November 21, 2024
Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers
Read more
Pathios Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Study of GPR65 Inhibitor, PTT-4256 in Patients with Advanced Solid Cancers
Read morePhase III trial results of novel triple combination pill for hypertension published in The Lancet
Read moreCUREator+ Opens Second Funding Round for Australian Biotech and Healthtech Innovators
Read moreBrandon BioCatalyst’s CUREator Incubator Boosts Preclinical and Health Security Biotech Innovations with $1.865m in funding.
Read moreENA Respiratory Progresses Phase Ib Study of its Dry Powder Formulation of Intranasal Innate Immunomodulator INNA-051
Read moreCatalYm Announces New Financing of $150M to Support Broad Phase 2b Development Program for Visugromab
Read moreUp to $5 million In Funding Available for Dementia and Cognitive Decline Innovations Through CUREator+
Read moreFunding Australia’s Future Economy: CUREator Deploys $7.21 Million to Propel local Life Sciences Potential
Read moreENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 – a First-in-Class Antiviral Innate Immunomodulator
Read moreAzura Ophthalmics to Present New Data Supporting the Potential of AZR-MD-001 to be the First Ophthalmic Keratolytic for Ocular Surface Diseases
Read moreAravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
Read moreCatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
Read moreVaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa
Read morePolyActiva reports promising clinical trial results for its 6-month sustained drug delivery,biodegradable ocular implant in glaucoma patients.
Read morePathios Therapeutics Awarded Innovate UK Grant to Evaluate First-in-Class Immunotherapy Approach in Models of Malignant Brain Cancer
Read moreGlyscend Therapeutics Appoints Sapan A. Shah, Ph.D., Accomplished Industry Executive, as Chief Executive Officer
Read moreVAXXAS AWARDED US$3.67 MILLION (AU$5.4 MILLION) FROM GLOBAL CHARITABLE FOUNDATION, WELLCOME, FOR HUMAN CLINICAL STUDY OF TYPHOID VACCINATION USING NEEDLE-FREE VACCINE PATCH
Read moreCicada Innovations to launch new health-focused hub in Westmead Health Precinct alongside Brandon BioCatalyst
Read moreVaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)
Read moreENA Respiratory Awarded $4.38 Million U.S. Department of Defense Agreement to Fund Development of Broad-Spectrum Antiviral INNA-051
Read moreEntact Bio Launches with $81 Million Series A to Develop Precision Medicines for Targeted Protein Enhancement
Read moreAzura Ophthalmics Announces Positive Results from Phase 2b Clinical Trial of AZR-MD-001 in Meibomian Gland Dysfunction
Read morePathios Therapeutics to Present Preclinical Data Highlighting Potential of GPR65 Inhibition as a Powerful Anti-Tumor Immunotherapy Strategy at SITC 2022
Read moreFirst in-human use of OncoRes Medical’s cancer imaging technology successful
Read moreOpinion: Taking the leap: transitioning from academia to industry – by Christina Kulis
Read moreAzura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)
Read moreGlyscend Therapeutics Releases New Phase 1 Biomarker Results and Initiates Phase 2 Clinical Trial under an IND for GLY-200 as a Potential First-in-Class Type 2 Diabetes Treatment
Read moreGeorge Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial
Read moreAustralian medical device company secures additional $12.5m to advance its breast cancer imaging system towards clinical trials
Read moreENA Respiratory Selected for BLUE KNIGHT™ to Accelerate Development of Pan-Antiviral Nasal Spray
Read moreParkinson’s patients benefit from revolutionary watch on the NHS to manage care at home
Read moreAravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
Read moreENA Respiratory and the COPD Foundation Partner to Develop Pan-Antiviral Nasal Spray
Read moreClinical trial begins in the UK to investigate 3-in-1 high blood pressure pill
Read moreHope offered to Australians suffering from a rare incurable fibrotic autoimmune disease, as clinical trials on new treatment commence
Read moreAustralia’s first national biotech incubator established with $40m MRFF investment
Read moreGlobal Kinetics Enters Remote Monitoring Business and Appoints New U.S. Commercial Leadership
Read more‘No amount could be enough’: Calls for Canberra to back biotech, as medtech firms await funding
Read moreAdelaide’s BioMed City is attracting strong clinical trial interest as its critical mass continues to grow
Read moreResearch on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals
Read moreMyricx Pharma Launches with £4.5M (AU$8.2M) Financing to Progress its Novel NMT inhibitors in Cancer
Read moreVaxxas Announces US$22 Million (A$30.6 Million) Award from U.S. Government to Advance Vaxxas Needle-Free HD-MAP™ Vaccine Patch Technology for Pandemic Response
Read moreBiomedical Translation Bridge Program grants $1m to develop a drug treatment for obesity-related health conditions
Read more$14m invested in University of Melbourne spin-out to create vaccine for periodontal gum disease
Read moreFDA Grants EBR Systems Breakthrough Device Designation Status for the WiSE Cardiac Resynchronization Therapy (CRT) System
Read moreQUE Oncology Appoints Dr. Julie Cherrington and Elizabeth Cermak to Board of Directors
Read morePolyActiva completes recruitment in key Phase I glaucoma implant safety study.
Read moreMRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis
Read moreAravax reveals positive Phase I trial results at world-leading allergy conference
Read morePerth tech takes out Australian start-up competition to join international finals
Read moreMRCF invests in San Diego ophthalmic biotech company, clinical trials to take place in Australia
Read moreLevel 9, 31 Queen Street
Melbourne VIC 3000
Phone +61 3 9657 0700
Email: info@brandonbiocatalyst.com
Suite 2.05, 1 York Street
Sydney NSW 2000
Phone +61 2 8227 7080
Email: info@brandonbiocatalyst.com
